Clinical Trials

344 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT05327647 2025-12-18

BicaBCa

160 enrolled

Phase 2 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT04386746 2025-11-17

GEMDOCE

27 enrolled 9 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT03914794 2025-10-03

A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors

30 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07189793 2025-09-24

OHAI-NMIBC-01

106 enrolled

Phase 2 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT04917809 2025-09-10

A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer

20 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT07100184 2025-08-03

RC48 in Combination With Radiotherapy for HER2-Expressing NMIBC Patients

30 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT07019220 2025-06-13

COBRA

47 enrolled

Non-Muscle Invasive Bladder Neoplasms, Neoplasms

NCT04375813 2025-05-15

eRapa

166 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT01697306 2025-01-30

The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer

120 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT04593862 2024-09-19

BRAVE

25 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Motor Activity

NCT06187506 2024-07-12

Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer

20 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06227065 2024-01-26

POLO

28 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT03379909 2023-09-21

TROJAN

49 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT05975151 2023-09-21

Efficacy and Safety of Pseudomonas Aeruginosa for Intermediate and High-risk Non-muscle Invasive Bladder Cancer

Phase 2 Unknown

63 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Pseudomonas Infections

NCT05957757 2023-08-31

RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression

20 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT05996952 2023-08-18

RC48-ADC in Adjuvant/Salvage Treatment of HER2 Positive Non-muscle-invasive Bladder Cancer

77 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT04311580 2023-06-22

Intravesical Electromotive Mitomycin After Bacillus Calmette-Guérin Failure

52 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT03549650 2022-03-04

Prevention and Management of Intravesical BCG-related Lower Urinary Tract Symptoms

Phase 2 Terminated

3 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Lower Urinary Tract Symptoms

NCT03950362 2019-05-16

PREVERT

Phase 2 Unknown

67 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT02075060 2017-04-06

IPOI vs IPOP

Phase 2 Unknown

54 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT02207608 2015-05-28

Influence of Hyaluronic Acid on Bacillus Calmette-Guérin Local Side Effects

30 enrolled 6 charts